Virbac (CHIX:VIRPP) Total Long-Term Assets: €1,122 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:VIRPP Virbac SA CHIX:VIRPP
94 GF Score
Price €344.00
GF Value €368.81
! 2 Warning Signs
View Full Analysis

What is Virbac Total Long-Term Assets?

Virbac CHIX:VIRPP +2.99% 94 Total Long-Term Assets is €1,122 Mil as of Dec. 2025. GuruFocus rates CHIX:VIRPP with a GF Score™ of 94/100 and a GF Value™ of €368.81. The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Virbac's Total Long-Term Assets for the quarter that ended in Dec. 2025 was €1,122 Mil.

Virbac Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Virbac's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac Total Long-Term Assets Chart

Virbac Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 576.88 610.09 684.25 1,004.40 1,122.28

Virbac Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 684.25 918.94 1,004.40 973.24 1,122.28
CHIX:VIRPP
94GF Score
Virbac SA CHIX:VIRPP
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virbac Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €1,122 Mil mean?
Virbac (CHIX:VIRPP) has a Total Long-Term Assets of €1,122 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Virbac and its competitors.
Is Virbac's Total Long-Term Assets too high?
Virbac's current Total Long-Term Assets is €1,122 Mil. Overall, Virbac has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Virbac's Total Long-Term Assets compare to LLY and JNJ?
Virbac's Total Long-Term Assets of €1,122 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Virbac and its competitors. Virbac's current Total Long-Term Assets is €1,122 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Virbac (CHIX:VIRPP) has a current Total Long-Term Assets of €1,122 Mil. The stock's GF Value™ is €368.81, compared to a current price of €344.00 — trading 6.7% below its estimated fair value. The current Total Long-Term Assets is €1,122 Mil. Virbac's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current Total Long-Term Assets is €1,122 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (CHIX:VIRPP) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €344.00 is trading 6.7% below its estimated GF Value™ of €368.81.

Key valuation signals for CHIX:VIRPP:

  • Total Long-Term Assets: €1,122 Mil
  • GF Value™: €368.81 vs. price of €344.00 (6.7% below fair value)
  • GF Score™: 94/100 with 2 warning signs

No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
94GF Score

Get the complete analysis for CHIX:VIRPP

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€344.00
Price
€368.81
GF Value